NEW YORK, Aug. 7 – Illumina met Wall Street expectations on Tuesday as it posted a second-quarter net loss of $5.9 million, or $0.20 per share, compared with $5.3 million, or $0.25, for the same period last year.

Total revenue in the quarter ended June 30 was $470,000, surpassing the $79,000 that the functional genomics company posted for the second quarter 2000, an increase it attributed to a strong performance by its oligo service business.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.